In her talk today Dr.Mikovits mentioned working with a substance called Peptide T. She mentioned that a trial had been run on individuals with CFS yeas ago with good results.
So far I have only read the Wiki page, but I am going to keep searching.
If anybody out there can find anything out about it, let's discuss it here.
This is what wiki has to say about it;
Peptide T- The first HIV entry inhibitor was discovered in 1986 by National Institutes of Health (NIH) researchers.[1] Peptide T, and its modified analog Dala1-peptide T-amide (DAPTA), the drug in clinical trials, is a short peptide derived from the HIV envelope protein gp120 which blocks binding[2] and infection[3] of viral strains which use the CCR5 receptor to infect cells.
Peptide T has several positive effects related to HIV disease and Neuro-AIDS.[4] A placebo-controlled, three site, 200+ patient NIH-funded clinical trial, which focused on neurocognitive improvements, was conducted between 1990 and 1995. The results showed that Peptide T was not significantly different from placebo on the study primary end points. However Peptide T was associated with improved performance in the subgroup of patients with more severe cognitive impairment.[5]
A long-delayed analysis of antiviral effects from the 1996 NIH study showed peripheral viral load (combined plasma and serum) was significantly reduced in the DAPTA-treated group.[6] An eleven person study for Peptide T effects on cellular viral load showed reductions in the persistently infected monocyte reservoir to undetectable levels in most of the patients.[7] Elimination of viral reservoirs, such as the monocytes, is an important treatment goal.[8] DAPTA has been shown to substantially suppress brain inflammation and block proinflammatory cytokine signaling pathways in a small animal model of Alzheimer's Disease[9].
[edit]References
^ Pert CB, Hill JM, Ruff MR, et al. (Dec 1986). "Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity". Proc Natl Acad Sci USA. 83 (23): 9254–8. PMID 3097649. PMC 387114.
^ Polianova MT, Ruscetti FW, Pert CB, Ruff MR (Aug 2005). "Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA)". Antiviral Res. 67 (2): 83–92. doi:10.1016/j.antiviral.2005.03.007. PMID 16002156.
^ Ruff MR, Melendez-Guerrero LM, Yang QE, et al. (Oct 2001). "Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5)". Antiviral Res. 52 (1): 63–75. PMID 11530189.
^ Ruff MR, Polianova M, Yang QE, Leoung GS, Ruscetti FW, Pert CB (Jan 2003). "Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors". Curr HIV Res. 1 (1): 51–67. PMID 15043212.
^ Heseltine PN, Goodkin K, Atkinson JH, et al. (Jan 1998). "Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment". Arch Neurol. 55 (1): 41–51. PMID 9443710.
^ Goodkin K, Vitiello B, Lyman WD, et al. (Jun 2006). "Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment". J Neurovirol. 12 (3): 178–89. doi:10.1080/13550280600827344. PMID 16877299.
^ Polianova MT, Ruscetti FW, Pert CB, et al. (Jul 2003). "Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA)". Peptides 24 (7): 1093–8. PMID 14499289.
^ Crowe SM, Sonza S (Sep 2000). "HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication". J Leukoc Biol. 68 (3): 345–50. PMID 10985250.
^ http://www.sciencedirect.com/scienc...serid=10&md5=0e811a9b1208ef21cdb36b1c72579de5
So far I have only read the Wiki page, but I am going to keep searching.
If anybody out there can find anything out about it, let's discuss it here.
This is what wiki has to say about it;
Peptide T- The first HIV entry inhibitor was discovered in 1986 by National Institutes of Health (NIH) researchers.[1] Peptide T, and its modified analog Dala1-peptide T-amide (DAPTA), the drug in clinical trials, is a short peptide derived from the HIV envelope protein gp120 which blocks binding[2] and infection[3] of viral strains which use the CCR5 receptor to infect cells.
Peptide T has several positive effects related to HIV disease and Neuro-AIDS.[4] A placebo-controlled, three site, 200+ patient NIH-funded clinical trial, which focused on neurocognitive improvements, was conducted between 1990 and 1995. The results showed that Peptide T was not significantly different from placebo on the study primary end points. However Peptide T was associated with improved performance in the subgroup of patients with more severe cognitive impairment.[5]
A long-delayed analysis of antiviral effects from the 1996 NIH study showed peripheral viral load (combined plasma and serum) was significantly reduced in the DAPTA-treated group.[6] An eleven person study for Peptide T effects on cellular viral load showed reductions in the persistently infected monocyte reservoir to undetectable levels in most of the patients.[7] Elimination of viral reservoirs, such as the monocytes, is an important treatment goal.[8] DAPTA has been shown to substantially suppress brain inflammation and block proinflammatory cytokine signaling pathways in a small animal model of Alzheimer's Disease[9].
[edit]References
^ Pert CB, Hill JM, Ruff MR, et al. (Dec 1986). "Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity". Proc Natl Acad Sci USA. 83 (23): 9254–8. PMID 3097649. PMC 387114.
^ Polianova MT, Ruscetti FW, Pert CB, Ruff MR (Aug 2005). "Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA)". Antiviral Res. 67 (2): 83–92. doi:10.1016/j.antiviral.2005.03.007. PMID 16002156.
^ Ruff MR, Melendez-Guerrero LM, Yang QE, et al. (Oct 2001). "Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5)". Antiviral Res. 52 (1): 63–75. PMID 11530189.
^ Ruff MR, Polianova M, Yang QE, Leoung GS, Ruscetti FW, Pert CB (Jan 2003). "Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors". Curr HIV Res. 1 (1): 51–67. PMID 15043212.
^ Heseltine PN, Goodkin K, Atkinson JH, et al. (Jan 1998). "Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment". Arch Neurol. 55 (1): 41–51. PMID 9443710.
^ Goodkin K, Vitiello B, Lyman WD, et al. (Jun 2006). "Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment". J Neurovirol. 12 (3): 178–89. doi:10.1080/13550280600827344. PMID 16877299.
^ Polianova MT, Ruscetti FW, Pert CB, et al. (Jul 2003). "Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA)". Peptides 24 (7): 1093–8. PMID 14499289.
^ Crowe SM, Sonza S (Sep 2000). "HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication". J Leukoc Biol. 68 (3): 345–50. PMID 10985250.
^ http://www.sciencedirect.com/scienc...serid=10&md5=0e811a9b1208ef21cdb36b1c72579de5